Patents Assigned to Government of the United States of America, repres
-
Publication number: 20100166707Abstract: Disclosed are methods involving the administration of an extracellular matrix (ECM)/metastasis modifier gene, e.g., Anakin, Necdin, CentaurinD3 (CentD3), Csf1r, Brd4, Pi16, and Luc7l, for the prevention or inhibition of metastasis or of tumor growth. Further disclosed are methods of characterizing a tumor or cancer in a subject comprising detecting (i) a single nucleotide polymorphism (SNP) in an Anakin gene or a Brd4 gene of the subject, (ii) an amino acid substitution in an Anakin protein in the subject, or (iii) a level of expression of an Anakin gene or a Brd4 gene in the subject. Methods of screening a compound for anti-cancer activity and use of a compound with anti-cancer activity for the preparation of a medicament to treat or prevent cancer in a subject are also disclosed. Also disclosed is a method of inhibiting Sipa-1 in a subject.Type: ApplicationFiled: February 23, 2007Publication date: July 1, 2010Applicants: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kent W. Hunter, Nigel Crawford, Douglas R. Lowy, Xiaolan Qian, Hoda Anton-Culver, Agryrios Ziogas
-
Publication number: 20090053184Abstract: Nucleic acids encoding antitumor TCRs recognizing MART-1, NY-ESO-1, and melanoma gp100 peptides; vectors and cells comprising the same; and methods of using the foregoing.Type: ApplicationFiled: September 13, 2004Publication date: February 26, 2009Applicant: Government of the United States of America, Repres ented by The Secretary, Department of HealthInventors: Richard A. Morgan, Steven A. Rosenberg
-
Publication number: 20080306012Abstract: The invention relates to compounds capable of releasing nitric oxide wherein the compounds comprise a saccharide and at least one nitric oxide-releasing diazeniumdiolate [N2O2] functional group, which is bonded directly to a carbon atom of the saccharide, and methods for preparing the same. The invention further comprises the treatment of biological disorders treatable by the administration of nitric oxide.Type: ApplicationFiled: October 16, 2006Publication date: December 11, 2008Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRES ENTED BY THE SECRETARY OF DEPARTMENT OF HEALTHInventors: Joseph A. Hrabie, Larry K. Keefer
-
Publication number: 20080167283Abstract: Disclosed are compounds of the formula (I) wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more C5-C8 cycloalkyl groups, or a C5-C12 cycloalkyl, which may be optionally substituted with one or more C1-C30 alkyl groups, R? is hydrogen or lower alkyl, R? is a C1-C30 alkyl or halo, and the bond between C14 and C15 can be a single bond or double bond. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof. These compounds can find use in treating a number of diseases or conditions such as hypogonadism, hypergonadism, osteoporosis, and anemia, in providing hormonal therapy and contraception, as an anabolic agent, and in suppressing the release of hormones such as the luteinizing hormone.Type: ApplicationFiled: January 24, 2006Publication date: July 10, 2008Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY, DEPAInventors: Richard P. Blye, Hyun K. Kim
-
Publication number: 20080095805Abstract: The invention provides a method comprising detecting autoantibodies to BORIS in a sample obtained from a mammal, as well as BORIS polypeptides and epitopes, and kits comprising the BORIS polypeptides and epitopes, and a method of inducing an immune response to BORIS in a mammal.Type: ApplicationFiled: September 21, 2005Publication date: April 24, 2008Applicant: Government of the United States of America, represInventors: Victor Lobanenkov, Dmitri Loukinov, Ziedulla Abdullaev, Svetlana Pack
-
Publication number: 20070173514Abstract: Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure of wherein the presence of each of R1 and R2 is optional and R1 and R2 are each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.Type: ApplicationFiled: December 9, 2004Publication date: July 26, 2007Applicant: The Government of United State of America as RepreInventors: Joel Moss, Arnold Kristof
-
Publication number: 20060165652Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.Type: ApplicationFiled: September 5, 2003Publication date: July 27, 2006Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY DHHSInventors: Mark Dudley, Steven Rosenberg, John Wunderlich
-
Publication number: 20050256143Abstract: Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3? are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocabonyl, whereas R3 and R3? do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.Type: ApplicationFiled: October 24, 2003Publication date: November 17, 2005Applicants: Government of the United States of America, repres ented by The Secretary, Department of Health and, Ewha Womans UniversityInventors: Lak Jeong, Kenneth Jacobson, Hyung Moon, Hea Kim
-
Publication number: 20050175980Abstract: A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis.Type: ApplicationFiled: April 9, 2003Publication date: August 11, 2005Applicant: Government of the United States of America, repres by the Secretary, Dept. of Health and Human Serv.Inventors: Steven Libutti, Mark Kayton
-
Publication number: 20050123473Abstract: Substituted 1,4,7-triazacyclononane-N,N,?N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: ApplicationFiled: June 3, 2003Publication date: June 9, 2005Applicant: Government of the United States of America, repres by the Secretary, Dept of Health and Human Ser.Inventors: Martin Brechbiel, Hyun-Soon Chong
-
Publication number: 20050096261Abstract: A conjugate of formula: V-(Y)a-Z-T: (I), T-X-B-(Y)a-Z-T?: (II), V-(Y)a Z-(Y?)a V?: (III), T-X-B-(Y)a-Z-(Y?)a-X?-B?-T?: (IV), V-(Y)a-Z-(Y?)aX-B-T: (V), V-(Y)a-Z-X-B-Z?-(Y?)a-(V?)b: (VI), or (W)a-(Y)b-[(Z)c-(Y?)d-(X-B)e-(Y?)f-(Z?)g]h-(Y . . .Type: ApplicationFiled: February 27, 2003Publication date: May 5, 2005Applicant: Government of the United States of America, repres ented by the Secreatary, Department of Health & HInventors: Zoltan Szekely, Humcha Hariprakasha, Marek Cholody, Christopher Michejda